To be held in conjunction with the American Diabetes Association’s 82nd Scientific Sessions
ADA Registration Information
Click the button above to register for the American Diabetes Association’s 82nd Scientific Sessions and our Corporate Symposium.
If you have already registered for Scientific Sessions, log in as a Non-Member using your e-mail address or as a Member using your e-mail address or professional member ID # and zip code and you will be able to add the Corporate Symposium to your existing registration. Select ‘Edit Registration’ and proceed through the registration pages to the Corporate Symposia. After making your selection, click ‘Next Page’ until you see your confirmation summary. You will receive a revised e-mail confirmation.
If you have any questions regarding your registration please contact the ADA Registration & Hotel Support Center at (866) 290-9910 (toll free US & Canada) or (415) 268-2086 (International) Monday-Friday, between the hours of 9 a.m. – 9 p.m. ET or send a message at http://ada.cmrushelp.com.
Sunday, June 05, 2022
6:45 PM – 7:00 PM CDT – Registration/Dinner
7:00 PM – 8:00 PM CDT – Symposium
Hilton New Orleans Riverside Hotel
Two Poydras Street
New Orleans, LA 70130
Meeting Room: St. Charles Ballroom
PROGRAM FEATURES
-
- Whiteboard animations
- Interactive, case-based learning environment
- Create your own Personalized Poster
FACULTY
 |
Richard E. Pratley, MD Samuel E. Crockett Chair in Diabetes Research Medical Director AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead AdventHealth Translational Research Institute Adjunct Professor of Medicine Johns Hopkins University School of Medicine Orlando, FL |
 |
Robert Toto, MD Professor Director, Clinical Nephrology Director, Patient-Oriented Research in Nephrology University of Texas Southwestern Medical Center Dallas, TX |
PROGRAM DESCRIPTION
This symposium is designed to review the importance of chronic kidney disease (CKD) risk reduction in patients with T2D, how to evaluate opportunities to screen for CKD risk in patients with T2D and target reductions in albuminuria, the manageability of hyperkalemia and uniqueness of novel therapy, and key takeaways and practice changes.
Target Audience
This activity is designed to meet the educational needs of physicians, nurse practitioners, and other health care professionals to ensure recognition of CKD risk in patients with T2D and novel strategies for modifying CKD risk and the risk of other chronic complications of T2D.
Learning Objectives
After completing the CME activity, learners should be better able to:
- Summarize the features of third-generation mineralocorticoid receptor antagonists with the pharmacologic features of prior agents
- Evaluate the characteristics of mineralocorticoid receptor antagonists in managing the progression of chronic kidney disease in patients with type 2 diabetes in terms of clinical data and place in therapy
- Update strategies for the management of hyperkalemia associated with novel mineralocorticoid receptor antagonist therapy as opposed to earlier-generation agents
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in caring for patients with T2DM.
Credits: 1.0 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.).
Please contact Med Learning Group prior to the live event at [email protected]
